Germany: Reform of European Pharmaceutical Legislation

An Overview of Recent Changes in the Licensing Procedure for Medicinal Products
Last Updated: 4 August 2004
Article by Jochen Eimer

It was only recently that the process of reforming European pharmaceutical legislation within the framework of European Commission proposal ‘Pharma Review 2001’ was finally completed, with the adoption of a pharmaceutical legislation package comprising a new Regulation (EC) No. 726/2004 and two amending Directives 2004/27/EC and 2004/28/EC by the European Parliament and the Council of the European Union on 17 December 2003 and 11 March 2004, respectively.

The main objective of this reform is to improve the current authorisation procedure in a way that strengthens the availability of innovative medicinal products and, at the same time, ensures the right balance between the competitiveness of the pharmaceutical industry, the completion of the single market, and a high level of public health within the enlarged European Union. We will look at the individual pieces of legislation ultimately agreed upon to reach this goal in practice in the course of this article. At the beginning, however, we will briefly introduce the different marketing authorisation procedures for medicinal products available in Europe to provide the reader with a better understanding of the regulatory framework in which the recent changes took place.

Background—European Procedures for Marketing Authorisation

Within the European Union there are three different forms of marketing authorisation procedures —the Centralised Procedure, the Mutual Recognition Procedure and the independent National Procedures. The latter two are also referred to as the Decentralised Procedures.

The Centralised Procedure is currently compulsory for all medicinal products that satisfy the criteria listed in Part A of the Annex to Regulation (EEC) No. 2309/93, i.e., products developed by certain biotechnological processes, and optional for all medicinal products that come under one of the criteria referred to in Part B of that Annex, i.e., certain other innovative products. In both cases, applications for marketing authorisation must be submitted to the European Agency for the Evaluation of Medicinal Products (EMEA). Following the Agency’s scientific evaluation and positive opinion, marketing authorisations will generally be granted by the European Commission after further consultation with the Member States through the relevant standing committee. Marketing authorisations granted under the Centralised Procedure are valid throughout the Community and confer the same rights and obligations in each of the Member States as a national marketing authorisation granted in a particular Member State.

All medicinal products for which the Centralised Procedure is not mandatory may be eligible for national marketing authorisations in one or more of the Member States. If medicinal products are to be authorised in more than one Member State, the marketing authorisations will generally be granted in the Mutual Recognition Procedure. This means that one Member State acts as Reference Member State which—after carrying out a complete assessment of the application—will issue the national marketing authorisation for that Member State. All other Member States in which the medicinal product are to be marketed are referred to as Concerned Member States, all of which will base their respective national marketing authorisation on the mutual recognition of the national marketing authorisation granted by the Reference Member State. That said, the independent National Procedures are generally limited to cases where either a complete review is being undertaken by the Reference Member State in the initial phase of the Mutual Recognition Procedure, or marketing authorisations are sought for one particular Member State only.

Reason for Reform

Under Article 71 of Regulation (EEC) No. 2309/93, which set up the Centralised Procedure for certain medicinal products for human and veterinary use and established the EMEA, the European Commission was asked to report within 6 years after the Regulation’s entry into force in 1995 on the experience of using this new form of centralised marketing authorisation procedure. In its report, the Commission concluded that, whilst the general principle and basic structure of the Centralised and Decentralised Procedure should be maintained, there was nevertheless a need to improve and fine-tune certain details regarding the operation of these authorisation procedures in practice, such as:

  • access to the Centralised Procedure;
  • availability of a fast track procedure;
  • regulatory data protection; and 
  • compassionate use.

The new Regulation and the two amending Directives reflect these initial recommendations by the European Commission, as this article explains.

Extension of the Centralised Procedure

The new legislation extends the current scope of the compulsory Centralised Procedure. Effective 20 November 2005, the Centralised Procedure will become mandatory for all medicinal products for human use containing a new active substance and indicated for the treatment of AIDS, cancer, neurodegenerative disorders and diabetes. It will also apply to medicinal products designated as orphan medicinal products pursuant to Regulation (EC) No. 141/2000. Following an initiative of the European Parliament, with effect from 20 May 2008, the compulsory Centralised Procedure will also cover medicinal products for the treatment of auto-immune diseases and other immune dysfunctions as well as viral diseases.

Marketing authorisations in the optional Centralised Procedure may be granted:

  1. for medicinal products containing new active substances not authorised in the EU on the date of entry into force of the new Regulation;
  2. for medicinal products which the applicants show constitute a significant therapeutic, scientific or technical innovation or that the granting of authorisation in accordance with the new Regulation is in the interests of patients or animal health at the EU level; or
  3. for immunological veterinary medicinal products for the treatment of animal diseases that are subject to EU prophylactic measures.

Procedures to Speed Up the Availability of Medicinal Products

To make certain human and veterinary medicinal products which are of major interest from the viewpoint of public or animal health and in particular because of their therapeutic innovation, available within the shortest possible time, the new Regulation provides for an "Accelerated Assessment Procedure". Once the Committee of the EMEA reviewing the application has accepted the applicant’s request for such a procedure, the time limit for the Committee to deliver its opinion is reduced from 210 days after receipt of a valid application to just 150 days.

Furthermore, the new Regulation enables Member States to make certain medicinal products available on a compassionate use basis before a marketing authorisation has been granted for them, as long as they qualify for the Centralised Procedure and, if no application for marketing authorisation has already been submitted, as long as they are at least undergoing clinical trials. Availability is limited to patients with a chronically or seriously debilitating or life-threatening disease for which satisfactory treatment with an authorised medicinal product is unavailable.

Regulatory Data Protection

One of the most debated issues of the reform was the protection of the pharmacological, toxicological and clinical data contained in the dossier of an original medicinal product against references by generic competitors.

Under the current regime, all medicinal products authorised under the Centralised Procedure benefit from a 10-year period of exclusivity. The same protection period is conferred upon medicinal products authorised in Belgium, Germany, France, Italy, the Netherlands, Sweden, the United Kingdom and Luxembourg, whereas Austria, Denmark, Finland, Greece, Ireland, Iceland, Norway, Portugal and Spain only grant data exclusivity for a period of 6 years.

Despite strong concerns being voiced from the 10 new Member States, who expect a huge negative impact on their national healthcare budgets due to the later availability of generic medicinal products, the new legislation implements a uniform extended period of regulatory data protection in all EU countries. Medicinal products authorised under the Centralised Procedure (both in compulsory and optional) as well as the Decentralised Procedure will now enjoy a period of data protection of 8 years and an additional 2 years of marketing protection. This means that generic manufacturers can submit an application for marketing authorisation 8 years after an originator product is first put on the market, but that the generic product cannot be marketed for a further 2 years after the end of that period. If one or more new therapeutic indications of significant clinical benefit are authorised within the first 8 years of data protection then the protection may be extended by one additional year, up to total of 11 years. For certain veterinary medicinal products, this protection can even add up to an overall period of 13 years.

Validity of Marketing Authorisation

At present, the initial term of validity of a marketing authorisation granted under the Centralised Procedure and in the Decentralised Procedure is 5 years. Whilst this situation will basically not change under the new legislation, a new regime will come into operation for renewals of initial authorisations.

In future, upon expiry of the initial five-year term, the marketing authorisation may be renewed upon request of the marketing authorisation holder, for an generally unlimited period of time. Requests for renewals have to be accompanied by supporting data such as a consolidated version of the file in respect of quality, safety and efficacy, and have to be submitted to the competent authority at least 6 months before the initial marketing authorisation ceases to be valid.

Once a marketing authorisation has been granted, the holder will now have to make use of it because any authorisation not followed by the actual placing on the market of the authorised product within 3 years of its granting will cease to be valid. This will equally apply to authorised products were previously marketed in the authorising Member State but which have not been present on the market for three consecutive years. To this end, the marketing authorisation holder must inform the competent authority of the dates of actual marketing of the medicinal product in the Member States, taking into account the various presentations authorised. Further notification has to be made if the product ceases to be placed on the market, either temporarily or permanently.

Further Changes

As a result of Regulation (EC) No 726/2004 entering into force, the name of the European Agency for the Evaluation of Medicinal Products will be changed to the European Medicines Agency. In addition, the tasks of the EMEA Scientific Committees have been redefined and now reflect to a greater extent a modern, service-oriented approach. In particular, future applicants for marketing authorisations will be able to obtain scientific advice from the Scientific Committees more generally and in greater depth. Further measures have been put in place to allow the development of advice, particularly for small and medium-sized companies.

Next Steps and Strategy

As mentioned above, major parts of the new Regulation will come into force on 20 November 2005. By 30 October 2005, Member States must have implemented Directives 2004/27/EC and 2004/28/EC into their national laws.

Given the particularly crucial issue of regulatory data protection, this time schedule may make it advisable for some manufacturers of innovative medicinal products to reconsider their timing strategies and so delay application for a new medicinal product to enjoy greater protection. This is because the new standards only apply to those medicinal products for which application for marketing authorisation is submitted after the date of entry into force of the new legislation. 

Copyright © 2007, Mayer, Brown, Rowe & Maw LLP. and/or Mayer Brown International LLP. This Mayer Brown article provides information and comments on legal issues and developments of interest. The foregoing is not a comprehensive treatment of the subject matter covered and is not intended to provide legal advice. Readers should seek specific legal advice before taking any action with respect to the matters discussed herein.

Mayer Brown is a combination of two limited liability partnerships: one named Mayer Brown LLP, established in Illinois, USA; and one named Mayer Brown International LLP, incorporated in England.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions